Clenbuterol
Also known as: Clen, Spiropent
Beta-2 Agonist | Thermogenic Fat Loss
Overview
Clenbuterol is a potent, long-acting beta-2 adrenergic receptor agonist originally developed for the treatment of asthma and other respiratory conditions. It is approved as a bronchodilator in many countries throughout Europe, Latin America, and Asia, but has never been approved for human use in the United States, where it is only approved for veterinary use in horses (Ventipulmin). In the context of bodybuilding and physique sports, clenbuterol is widely used as a thermogenic agent during cutting phases to accelerate fat loss while preserving lean muscle mass. Its stimulatory effects on the sympathetic nervous system increase basal metabolic rate, core body temperature, and lipolysis. Unlike anabolic steroids, clenbuterol does not directly promote muscle growth in humans at typical doses, though animal studies have demonstrated significant anabolic effects in livestock, which led to its controversial use in meat production in some countries.
Key benefits
- Increased basal metabolic rate and thermogenesis for accelerated fat loss
- Preferential mobilization of stored body fat through enhanced lipolysis
- Anti-catabolic effects that help preserve lean muscle mass during caloric restriction
- Bronchodilation and improved respiratory capacity during intense exercise
- Appetite suppression in many users, supporting adherence to caloric deficit
- Oral administration with no injections required
Mechanism of action
Clenbuterol selectively binds to beta-2 adrenergic receptors on cell surfaces, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL) in adipose tissue, directly stimulating lipolysis and the release of free fatty acids for oxidation. In smooth muscle tissue, beta-2 activation causes relaxation of bronchial airways, which accounts for its therapeutic use in asthma. Clenbuterol also stimulates mitochondrial uncoupling and increases thermogenesis, raising basal metabolic rate by an estimated 5-10%. Additionally, clenbuterol has mild anti-catabolic properties in humans, potentially reducing muscle protein breakdown during caloric restriction through beta-2 receptor-mediated inhibition of the ubiquitin-proteasome pathway. A significant limitation is the downregulation of beta-2 receptors with continuous use, typically occurring within 2-3 weeks, which diminishes the thermogenic effect and necessitates cycling protocols or co-administration of ketotifen (an antihistamine that upregulates beta receptors).
Molecular data
- Type
- Sympathomimetic amine (C12H18Cl2N2O)
- Half-life
- ~36 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Fat Loss / Body Composition
Respiratory
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 20 mcg/day ramping to 80-120 mcg/day | Once daily (morning) | — |
| — | 20 mcg/day ramping to 80-120 mcg/day | Once daily (morning) | — |
| — | 20 mcg/day ramping to 40-80 mcg/day | Once daily (morning) | — |
Protocol variations
Alternative cycling patterns reported in the literature and community.
2 Weeks On / 2 Weeks Off
The most widely used clenbuterol protocol. Users ramp the dose up over the first few days, maintain the peak dose for the remainder of two weeks, then discontinue completely for two weeks to allow beta-2 receptors to resensitize. During off weeks, some users substitute ephedrine/caffeine as an alternative thermogenic. This cycle is repeated for the duration of the cutting phase.
Continuous with Ketotifen
Ketotifen is an antihistamine (H1 receptor antagonist) that has been shown to upregulate beta-2 adrenergic receptors. By adding ketotifen at 1-2 mg nightly starting in the second week, users can extend clenbuterol cycles to 6-8 weeks continuously. This avoids the off periods of the traditional protocol and may produce more consistent fat loss over the cycle duration. The main drawback is that ketotifen causes drowsiness and increased appetite in some users.
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Tremors and shaking (especially hands) - most pronounced in the first 3-5 days
- Tachycardia (elevated heart rate, typically 10-20 bpm above baseline)
- Insomnia and sleep disturbance, particularly with afternoon or evening dosing
- Muscle cramps (calves, forearms, back) due to taurine depletion
- Increased sweating and elevated body temperature
- Headaches, particularly during dose ramp-up
- Nervousness, anxiety, and restlessness
- Increased blood pressure
Rare side effects
- Cardiac hypertrophy (enlargement of the heart muscle) with chronic or high-dose use
- Cardiac arrhythmias including atrial fibrillation and ventricular tachycardia
- Severe hypokalemia (potassium depletion) leading to dangerous cardiac rhythm disturbances
- Myocardial ischemia in individuals with pre-existing cardiovascular disease
- Rhabdomyolysis (muscle breakdown) at very high doses or in combination with intense exercise
Contraindications
- Pre-existing cardiovascular disease, cardiomyopathy, or arrhythmia
- Uncontrolled hypertension
- Hyperthyroidism or thyrotoxicosis
- Hypokalemia or electrolyte imbalances
- Known hypersensitivity to clenbuterol or sympathomimetic amines
- Concurrent use of other stimulants (ephedrine, amphetamines) or MAO inhibitors
- Pregnancy or breastfeeding
Monitoring
- Resting heart rate: daily (keep below 100 bpm; reduce dose if consistently elevated above baseline by more than 20 bpm)
- Blood pressure: at least weekly during use
- Serum potassium and taurine status: baseline and mid-cycle if available
- Electrocardiogram (ECG): recommended at baseline for individuals over 40 or with cardiac risk factors
- Body temperature: first few days to confirm thermogenic response (expect 0.5-1.0F increase)
References
Primary literature and clinical-trial data informing this entry.